Nanmo Biological: It is expected that the net profit for the first half of 2026 will be between 8 million and 10 million yuan, a year-on-year decrease of 55.97% to 44.96%.

Nanmo Biological announced that it expects its operating income in the first half of 2026 to be between 216 million yuan and 250 million yuan, a year-on-year increase of 10.34% to 27.71%; it anticipates a net profit attributable to the parent company of 8 million to 10 million yuan, a decrease of 55.97% to 44.96% compared to 18.1674 million yuan in the same period of 2025. The decline in net profit is mainly due to a significant increase in share-based payment expenses compared to the same period in 2025, and in the same period of 2025, the expected performance targets of the restricted stock incentive plan failed to be met, which reduced the amount of share-based payments. After excluding the impact of share-based payments, the net profit attributable to the parent company is expected to be between 13 million yuan and 15.8 million yuan, a year-on-year increase of 47.27% to 78.99%. This performance forecast has not been audited.